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Can nutrition support healthy cognitive ageing 
and reduce dementia risk?
Amy Jennings and colleagues describe the evidence and potential for food and food bioactive 
components to reduce the population prevalence of dementia
Around 50 million people world-wide have dementia, the main form of which is Alzheimer’s disease. Dementia is a major cause of disability and depend-
ency in older adults and, owing to expand-
ing and ageing populations, its prevalence 
is expected to almost triple by 2050. This 
increase is being partly offset by decreas-
ing age standardised dementia rates in 
some high income countries, attributed to 
more years of education and improved car-
diovascular health.1 In England and Wales, 
dementia is the first and second leading 
cause of death in women and men, respec-
tively, responsible for 16.3% and 8.7% of 
total mortality in 2017 (www.ons.gov.uk). 
Almost two thirds of cases of dementia 
are in women. The cause of this difference 
between the sexes is poorly understood.2
Interventions to improve cognition and reduce 
dementia risk
No licensed drugs are available that pre-
vent or reverse dementia. For Alzheimer’s 
disease four drugs are used to treat symp-
toms temporarily (donepezil, rivastigmine, 
galantamine, and memantine). Therefore, 
behaviour which prevents or delays pro-
gression of neuropathology and brain 
vascular dysfunction could help to reduce 
the individual risk and population burden 
of the disease. The 2014 report, “The tra-
jectory of dementia in the UK–making a 
difference,” estimated that a two or five 
year delay in the onset of dementia would 
reduce the number of people with the dis-
ease in the UK by 19% and 33%. respec-
tively, by 2050.3 In a US based analysis, 
Brookmeyer and colleagues predicted that 
interventions associated with a five year 
delay would almost halve cases of dementia 
over 50 years.4
It is estimated that about one third of 
cases of Alzheimer’s disease worldwide 
are attributable to modifiable risk 
factors,5 many of which are nutrition and 
lifestyle dependent (depression, mid-life 
obesity, mid-life hypertension, and type 
2 diabetes). Cardiometabolic health is a 
major determinant of age related cognition 
function and risk of dementia. Research 
into the role of nutrition in age related 
cognitive decline is in its relative infancy 
compared with other chronic conditions, 
such as cardiovascular diseases, type 
2 diabetes mellitus, osteoporosis, and 
gastrointestinal disorders.
Although the results are not fully 
consistent,6 a growing body of prospective 
cohort evidence shows that bioactive 
components of food are associated with a 
reduced risk of dementia.7 8 Much of the 
research has considered dementia as a 
composite, despite the recognition that 
owing to differences in pathology, dementia 
subtypes (eg, Alzheimer’s disease, vascular 
dementia, dementia with Lewy bodies) are 
probably influenced by differing dietary 
factors. Furthermore, a large retrospective 
cohort study9 has shown that behaviour, 
including a healthy diet, partly mitigates 
the penetrance of a high dementia genetic 
risk score. Model systems have provided 
insight into the potential underlying 
molecular and physiological mechanisms 
for the associations observed, including 
improved cardiometabolic health and 
brain perfusion, and direct effects within 
the brain on neuronal function, energy 
metabolism, and β amyloid processing. 
The randomised controlled trial evidence 
is more limited and less convincing,7 10 with 
cognition and brain volume (as assessed by 
MRI) as the main study endpoints, and few 
primary prevention randomised controlled 
trials with incident dementia as an outcome 
measure.
Nutrition and cognition
Some evidence suggests that individual 
food bioactive components protect cogni-
tive health (for review see Scarmeas et al8), 
including B vitamins, antioxidant vitamins, 
selenium, vitamin D, medium chain triglyc-
erides, and long chain omega-3 fatty acids 
(see supplementary table on bmj.com). This 
evidence is not conclusive, however. Any 
effects of intervention with such individual 
components are most likely to appear after 
long term exposure, and in those with a 
low baseline habitual intake. Evidence that 
nutrition has a beneficial effect on brain 
function is stronger for healthy dietary 
patterns, probably because the synergis-
tic effect of several bioactive components 
affects many physiological processes and 
signalling pathways underlying cognitive 
function and decline. Intuitively, one would 
predict that the effect of nutrition would be 
more evident in people who are still cogni-
tively healthy or prodromal, rather than in 
those with diagnosed dementia, where sig-
nificant neuronal loss has already occurred, 
but this has not been rigorously tested.
Here we focus on fish/the omega-3 
fatty acid docosahexaenoic acids (DHAs), 
ketogenic interventions, and a plant based 
dietary pattern (eg, Mediterranean diet) 
as approaches to nutrition with a strong 
potential to mitigate age related cognitive 
decline. The state of advancement of 
knowledge and inconsistencies in these 
areas provide insight into the research 
approaches used and the challenges 
encountered in confirming nutrition-
cognition causal relations, especially 
during ageing.
Key Messages
•   Global prevalence of dementia is pre-
dicted to almost triple by 2050 and 
no current treatments are effective
•   Improved eating behaviour could 
reduce the risk and population preva-
lence of dementia
•   Owing to dementia’s multifactorial 
aetiology, multiple dietary compo-
nents that target several physiological 
pathways and risk factors simultane-
ously are needed
•   Changes to dietary patterns and foods 
(rather than single dietary compo-
nents) therefore hold most promise to 
meaningfully improve cognition 
•   Randomised controlled trials with 
robust validated cognitive outcomes 
are needed to support the prospective 
cohort evidence, establish efficacy and 
effect size, and inform public health 
policy
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Omega-3 fatty acids and improved brain 
function
Oily fish, which includes salmon, mackerel, 
herring, fresh tuna, and sardines, are the 
almost exclusive dietary source of the long 
chain n-3 fatty acids, eicosapentaenoic 
acid and docosahexaenoic acid (DHA). 
Algal oil capsules provide a vegan source 
of DHA. The brain is highly enriched in 
DHA, which constitutes 15% of brain lipids 
compared with less than 5% in most other 
tissues.11 The role of DHA in the developing 
fetal and infant brain is widely accepted. 
In prospective cohort studies, high fish 
and DHA intake has been consistently 
associated with improved cognitive health 
in older age, with a 10-30% reduced risk 
of Alzheimer’s disease and death, brain 
atrophy, and cognitive decline, and effect 
sizes equivalent to two to four years of age-
ing12-16; there is some indication of greater 
effects in women.15 In a meta-analysis of 
21 cohort studies, a 100 mg increment of 
dietary DHA was associated with lower 
risks of dementia (relative risk 0.86, 95% 
confidence interval 0.76 to 0.96) and Alz-
heimer’s disease (0.63, 0.51 to 0.76).14 
Fish is also a source of multiple nutrients 
needed by the brain, including vitamin B12, 
selenium, and vitamin D, which may con-
tribute to the observed cognitive benefits. 
Thus, where possible, fish itself rather than 
fish oil supplements is recommended as a 
source of DHA.
For a dietary component such as 
DHA/fish, which could be considered a 
signature of an overall healthy diet (such 
as a Mediterranean-style diet discussed 
below) and healthy behaviour, the 
possibility of residual confounding should 
be considered, as some of the cognitive 
benefits associated with DHA seen in 
prospective cohorts could be due to a yet 
unknown factor associated with intake,17 
and the benefits associated with eating fish 
and DHA could be biased.18
A number of randomised controlled 
trials have reported mixed findings with 
DHA supplementation over periods of up 
to three years (see supplementary data). 
DHA is one of the bioactive ingredients in 
Souvenaid (Fortasyn Connect) medicinal 
food, designed to support cognitive ageing. 
In the LipiDiDiet trial, Souvenaid had no 
effect on the primary outcome measure, 
but was associated with an improved 
clinical dementia rating score and reduced 
hippocampal (a main brain region affected 
in Alzheimer’s disease) atrophy.19
Response to DHA interventions is 
heterogeneous and may partly depend 
on DHA and cognitive status at baseline. 
Cognitive benefits are reported for healthy 
younger adults20 and in mild cognitive 
impairment,21 in contrast to those with 
more advanced disease.22 Early indications 
are that APOE4 carriers (25% of white 
populations), and particularly older 
women with the APOE4 variant, may 
have lower brain DHA uptake and status, 
and would benefit from higher dose DHA 
supplementation.2 23 24 For DHA and other 
dietary components, several variables 
need to be considered, including delivery 
to the brain and time taken to reach a 
steady state, and whether the cognitive 
benefits are direct effects on brain 
structure, perfusion, or metabolism, or an 
indirect effect attributable to, for example, 
cardiometabolic health. Brain DHA half 
life is estimated to be 2.5 years,25 and thus 
supplementation periods of at least a year 
are probably needed to detect the cognitive 
benefits associated with DHA enrichment 
of neuronal cells, and effects on β-amyloid 
and tau protein metabolism and synaptic 
plasticity.2 26
Brain glucose use, ketones, and cognitive 
health
One of the challenges facing the ageing 
brain is a chronic deficit in brain glucose 
uptake. Cognitively healthy older adults 
have about 7-8% lower brain glucose 
uptake than younger adults, a decline 
accentuated in mild cognitive impairment 
(the prodromal phase of Alzheimer’s dis-
ease) and even more so in Alzheimer’s dis-
ease itself.27 Although low brain glucose 
could be a consequence of the disease pro-
cess, two facets of the declining glucose 
uptake, brain cell loss, cognitive decline 
continuum suggest that this interpreta-
tion should be reconsidered. Firstly, brain 
glucose uptake is already lower in those at 
risk of Alzheimer’s disease (that is, older 
age but still cognitively normal, carriers 
of the presenilin mutation or APOE4, or 
type 2 diabetes) but before their cognition 
declines.28
Secondly, studies with positron emission 
tomography imaging and a ketone tracer 
(11C-acetoacetate) show that, unlike 
glucose, brain ketone uptake is normal 
during ageing, mild cognitive impairment, 
and Alzheimer’s disease.29-31 Ketones are 
the brain’s second most important fuel 
and, as for glucose, brain ketone uptake 
is an active, transporter mediated process. 
Hence, many of the brain cells in which 
glucose metabolism is deteriorating 
owing to age or Alzheimer’s disease are 
not apoptotic (or dead) because they can 
still metabolise ketones. Rather, they are 
gradually becoming energy (glucose) 
starved, but perhaps their function could 
be revived or maintained by ketones, an 
emerging therapeutic concept called “brain 
energy rescue”.32
Under normal circumstances, glucose 
supplies about 95% of the brain’s fuel. It 
is, however, effectively replaced by ketones 
(β-hydroxybutyrate and acetoacetate) 
when dietary carbohydrate or total dietary 
energy is limited. Furthermore, when 
a ketogenic supplement is included in 
the diet, the brain of someone with mild 
cognitive impairment or Alzheimer’s 
disease uses ketones in direct proportion 
to the increased ketones provided by the 
circulation, thereby sparing brain glucose 
use.33 34
Recent experimental clinical studies 
have shown that brain energy rescue 
with ketones is associated with improved 
cognitive outcomes in both mild cognitive 
impairment and Alzheimer’s disease. 
These studies used either a very low 
carbohydrate (ketogenic) diet35-37 or 
20-30 g/day of ketogenic medium chain 
triglyceride supplement.34 38 39 With ketone 
positron emission tomography imaging, 
two of these studies showed that not only 
did ketones access the brain of someone 
with mild cognitive impairment37 but 
that improvement on several cognitive 
tests was directly proportional to the rise 
in plasma ketones,34 implying a direct 
mechanistic link between restoration of 
brain energy levels by ketones and the 
improved cognitive performance. Ketogenic 
interventions may also be disease 
modifying because preclinical and clinical 
reports show that the neuropathological 
process involving accumulation of the 
dementia associated proteins, amyloid β 
and phosphorylated tau, can be partially 
blocked by ketogenic supplements.37 40 41 
These results are encouraging but comp-
liance is low with ketogenic diets, and 
ketogenic medium chain triglycerides can 
cause gastrointestinal discomfort. Thus 
more work is needed to optimise ketogenic 
interventions (dose, duration, formulation) 
and test them in larger randomised 
controlled trials in order to convincingly 
assess their efficacy in improving 
cognitive outcomes in people with mild 
cognitive impairment or Alzheimer’s 
disease. Ketogenic interventions may 
indirectly affect cognitive outcomes, in 
part, by improving insulin sensitivity or 
stimulating weight loss; they would also 
be predicted to be more efficient in slowing 
down Alzheimer’s disease if combined with 
exercise.42 Given the emerging evidence 
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for the cardiometabolic safety of the 
ketogenic diet and the growing interest 
in its use to treat type 2 diabetes,43 a long 
term controlled intervention assessing its 
effect on cognitive outcomes and risk of 
Alzheimer’s disease is warranted.
Dietary patterns and cognitive health
Recent research has moved away from the 
reductionist approach to nutrition, health, 
and chronic disease,17 and focused on the 
effect of dietary patterns, such as the Medi-
terranean diet, DASH (Dietary Approaches 
to Stop Hypertension) diet, and the hybrid 
MIND (Mediterranean-DASH Intervention 
for Neurodegenerative Delay) diet. Addi-
tionally, the World Health Organization 
and Public Health England have advo-
cated whole diet approaches to delay or 
prevent cognitive decline.7 44 A Mediter-
ranean diet is high in fruits, vegetables, 
olive oil, whole grains, unsaturated fatty 
acids, and fish, with restrictions of red 
meat, and moderate but regular drinking 
of alcohol. A meta-analysis of 34 168 par-
ticipants showed that higher adherence to 
a Mediterranean diet was associated with 
a 21% reduced risk of developing cogni-
tive disorders and a 40% reduced risk of 
Alzheimer’s disease.45 In a recent analysis 
of the EPIC (European Prospective Investi-
gation into Cancer and Nutrition)-Norfolk 
cohort, the global cognitive benefit of high 
versus low adherence to a Mediterranean 
diet was equivalent to 1.7 fewer years of 
cognitive ageing.46
Numerous foods in modern Western-
style diets are not traditionally included 
in a Mediterranean diet, such as high 
fat dairy products, processed meats, 
carbonated drinks, sweets, and pastries. 
The PREDIMED, MIND, and DASH diets 
are Mediterranean-style diets and all 
three improved cognitive outcomes,47 48 
with respectively a 53%, 54%, and 39% 
lower incidence of Alzheimer’s disease 
after 4.5 years.49 A multidomain lifestyle 
intervention trial (FINGER), which 
included modified eating behaviour as one 
of four concurrent interventions, improved 
cognitive outcomes. After two years, a 
25% improvement in global cognition 
(as assessed by the neuropsychological 
test battery), and higher executive 
function (150%) and processing speed 
(89%) was evident in the intervention 
versus control group.50 51 These findings 
indicate that whole diet approaches 
that encourage Mediterranean-style 
elements and discourage energy dense 
foods typical of a Western-style diet are 
beneficial for cognitive health. Although 
the PREDIMED study reported a lower 
prevalence of mild cognitive impairment 
after a Mediterranean diet,52 longitudinal 
randomised controlled trials, with 
incident mild cognitive impairment/
Alzheimer’s disease as the primary end 
point, are still lacking.
The totality of evidence supports the 
protective effect of adherence to diets rich 
in whole foods for dementia and cognitive 
function, but there are inconsistencies 
within and between diets.45 Contradictory 
findings may be due to the geographical 
region, with a recent systematic review 
reporting that 80% of cohort studies 
conducted in Mediterranean regions 
showed significant associations with 
cognitive health, compared with only 50% 
in non-Mediterranean regions.53 Possible 
reasons for this geographical disparity are 
firstly, diet adherence scores may reflect 
different food patterns in Mediterranean 
versus non-Mediterranean countries—for 
example, olive oil, fish, and legumes are 
more commonly eaten in Mediterranean 
regions; secondly, adherence scores do 
not consider foods reflective of Western-
style diets in non-Mediterranean regions; 
or, thirdly, in Mediterranean regions the 
Mediterranean diet score is “capturing” 
a lifestyle with characteristics protective 
of cognitive decline, including increased 
social interactions when eating, and 
physical activity.54 55
Heterogeneity in dietary response could 
also be due to individual differences 
in nutrient metabolism. Beneficial 
changes in the gut microbiome, together 
with taxonomic shifts in microbiota 
composition, have been seen in those 
following plant based diets.56 A higher 
intake of plant based foods is associated 
with lower trimethylamine oxide levels 
and increased faecal short chain fatty 
acids, fibre degrading microbiota, and 
gut microbial diversity.57 58 These gut 
microbial changes are linked to the gut-
brain axis. Thus short chain fatty acids—
in particular, butyrate, enhance brain 
derived neurotrophic factor expression, 
and trimethylamine oxide is linked to 
reduced expression of synaptic plasticity 
related proteins, including N-methyl-
D-aspartate-receptors, both important 
factors for learning and memory.59 60 If 
the microbiome can affect the gut-brain 
axis then diet induced changes in the 
gut microbiota, through plant based or 
Mediterranean diets associated with 
higher consumption of fibre, polyphenols, 
and probiotics could affect development of 
cognitive impairment. Equally, microbiome 
speciation and metabolism could influence 
the cognitive response to dietary change 
and may emerge as a tractable target for 
interventions.
In addition to the nutrients needed for 
brain function, the reduced content of 
refined sugars in Mediterranean-type diets 
may also help to improve glucose tolerance. 
This would help the ageing brain meet its 
energy needs (both glucose and ketones) by 
reducing creeping insulin resistance during 
ageing, thereby improving the chance of 
maintaining optimal cognition.
Conclusions
Prospective cohort evidence suggests that 
a change in eating behaviour may delay 
the onset of dementia, possibly by several 
years. The trial evidence to date is reliant 
on cognitive or other surrogate markers 
of dementia risk with often, uncertain 
prognostic value, and lacking sensitiv-
ity and specificity to dementia subtypes. 
Longitudinal randomised controlled tri-
als with robust cognitive outcomes are 
still needed, ideally, with incident disease 
(either dementia or mild cognitive impair-
ment) as the primary outcome. Metabolic 
and preclinical studies will help to provide 
insights into mechanisms so as to collec-
tively provide the evidence needed to make 
causal inferences, fully establish efficacy, 
and inform policy.17 Randomised controlled 
trials are often expensive and long term. 
They should be supported by validated 
imaging and biochemical biomarkers of 
disease, both to select at risk and respon-
sive subgroups, and to screen potentially 
effective interventions.
Are we yet in a position to provide 
dietary guidelines specifically to promote 
cognitive health and reduce the risk of 
dementia in later life? Global and national 
dietary macronutrient (particularly fat 
and carbohydrate) and food guidelines 
(eg, eating fruit and vegetables and 
reducing salt) are, in large part, based 
on the management of cardiometabolic 
risk (obesity, cardiovascular diseases, 
and type 2 diabetes mellitus). Given the 
established importance of cardiometabolic 
health on cognitive function (especially in 
mid-life), greater adherence to existing 
dietary recommendations is likely to 
reduce the incidence of dementia. To 
develop dietary guidelines specifically 
focused on prevention of dementia or 
improving mild cognitive decline, further 
research is needed to gain insight into 
which dietary strategies most effectively 
improve neuronal function and reduce 
neuropathology.
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